Key result
Antiplatelet therapies, including aspirin, ADP receptor antagonists, and GP IIb/IIIa inhibitors, improve outcomes in patients with established atherothrombotic vascular disease.
This review summarizes the established efficacy and safety of various antiplatelet therapies in the management of atherothrombotic vascular disease.
Antiplatelet use may continue in established vascular disease; leaves open optimal regimens and durations for prospective trials.
Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease.
No takes yet. Share an insight, caveat, or question.
Παπαθανασίου et al. (2008) conducted a review in Atherothrombotic vascular disease. Antiplatelet therapy (aspirin, ADP receptor antagonists, GP IIb/IIIa inhibitors) was evaluated. Antiplatelet therapies, including aspirin, ADP receptor antagonists, and GP IIb/IIIa inhibitors, improve outcomes in patients with established atherothrombotic vascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: